Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3773 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

GSK accused of drug trial cover-up

Documents obtained by the program show that tests had failed to prove that Seroxat was a safe or beneficial treatment for depressed children, according to the BBC. Seroxat

Breakthrough in diabetes-related blindness made

The Juvenile Diabetes Research Foundation said that the findings could suggest new therapeutic targets for the treatment of proliferative diabetic retinopathy and macular edema, and could provide new

Introgen cancer vaccine shows promise

Patients in the study achieved a 52% objective tumor response rate and 41% of patients were still alive one year after receiving the immunotherapy known as INGN 225.

Par receives approval for generic heart drug

Propranolol hydrochloride (HCl) extended release (ER) is the generic equivalent of Wyeth Pharmaceuticals’ Inderal LA and is used to treat hypertension, angina pectoris due to coronary atherosclerosis, migraine

FTC increases waiting period on Genentech deal

The second request extends the waiting period imposed by the Hart-Scott-Rodino Act. The expiration of the waiting period is a condition of the acquisition. Genentech anticipates that the

Schering-Plough Q4 profit up

For the 2006 fourth quarter, the company reported net income available to common shareholders of $182 million or 12 cents per share. This had increased from the 2005

Durect signs manufacturing agreement with Hospira

Under the agreement, Hospira's contract manufacturing services will provide Durect's clinical and commercial supplies of Posidur on a worldwide basis. The two parties have begun manufacturing development activities

Thailand rejects Plavix, Kaletra patents

Both drugs have been issued with a compulsory license in order to make them more affordable, without the permission of the patent holder. Under World Trade Organization (WTO)